-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$21.7518.4% Upside
Recent Analyst Forecasts and Stock Ratings
Travere Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Travere Therapeutics, Inc.?
Travere Therapeutics, Inc. has been rated by research analysts at Evercore ISI, Wells Fargo, Bank of America Securities, Barclays, Guggenheim, H.C. Wainwright in the past 90 days.